Arrowhead starts PhI of RNA hep B drug; InSite Vision welcomes positive PhIII data for drug-delivering eye drop;

> Arrowhead began a Phase I trial of its RNAi drug ARC-520 for the treatment of chronic hepatitis B. The company expects to complete the trial in the fourth quarter of 2013. Release

> InSite Vision hailed positive Phase III results of its AzaSite Plus and DexaSite eye drops to treat blepharitis. Release

> Alliqua began a preclinical proof-of-principle study of its experimental hydrogel patch that contains lidocaine, a pain drug the company hopes to develop for the treatment of localized acute pain, including postoperative pain, back pain, sports injuries and arthritis. Release

> Inovio Pharmaceuticals ($INO) found that its electroporation technology significantly enhanced the ability of a DNA therapy to stimulate blood vessel growth for the treatment of critical limb ischemia and other forms of peripheral arterial disease. Release

> Kala Pharmaceuticals will present data relating to the company's mucosal-penetrating particle technology for drug delivery to the front and back of the eye at the Controlled Release Society 2013 Annual Meeting in Honolulu, HI. Release

Suggested Articles

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.